Tango Therapeutics, Inc.
NASDAQ:TNGXBiotechnology
-$3.24 today
- Market cap
- $3.71B
- Beta
- 1.19
- P/E (TTM)
- -38.9
- EPS (TTM)
- -$0.75
Volume 2.75M
Average 3.67M
TNGX EBITDA Margin
EBITDA as a percentage of revenue.
Tango Therapeutics, Inc.NASDAQ: TNGX
EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026
EBITDA Margin not reported for Q3 FY2026
Over 3 fiscal years it widened by 269.3 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 8 analysts of -2792.6% for the fiscal year ending Dec 2026, down from -159.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- —— QoQ
- Last fiscal yearDec 2025
- -159.2%+144.1 pp YoY
- LTMSep 2026
- —— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | +144.1 pp | -2633.4 pp | -2777.6 pp |
| 3 years | +269.3 pp | -367.0 pp | -636.3 pp |
| 5 years | +179.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -159.2%
- Year-over-year change
- +144.1pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -159.2% | +144.1pp |
| FY2024 | 2024-12-31 | -303.3% | -31.7pp |
| FY2023 | 2023-12-31 | -271.6% | +156.9pp |
| FY2022 | 2022-12-31 | -428.5% | -274.5pp |
| FY2021 | 2021-12-31 | -154.0% | — |
EBITDA Margin vs competitors
How TNGX compares with its peers on the latest reported figures
- TNGX's FY2025 EBITDA Margin of -159.2% is the 4th highest of the 8 companies compared; the peer median is -257.0%.
- Its year-over-year change of +144.1 pp is the 6th highest of 8, against a peer median of +927.4 pp.
- Over three fiscal years its change of +269.3 pp compares with a peer median of +147.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Aug 2026 | 46.0% | +315.4 pp | +147.4 pp | |
| LTM Mar 2026 | -60.1% | +4260.2 pp | +61.2 pp | |
| LTM Jun 2026 | -74.8% | +1326.6 pp | — | |
| FY2025 | -159.2% | +144.1 pp | +269.3 pp | |
| LTM Mar 2026 | -257.0% | +77.3 pp | +319.4 pp | |
| LTM Mar 2026 | -287.9% | -44.6 pp | +113.4 pp | |
| LTM Mar 2026 | -455.3% | +1345.3 pp | — | |
| LTM Jun 2026 | -2742.3% | +927.4 pp | +20440.0 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding TNGX) | -257.0% | +927.4 pp | +147.4 pp | |
Competitors are the stored peer set for TNGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.04M | 24.86M | 36.53M | 42.07M | 62.38M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.28M |
| Gross Profit | 37.04M | 24.86M | 36.53M | 42.07M | 60.1M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 96.3% |
| Research & Development | 77.64M | 105.91M | 115.2M | 143.92M | 132.17M |
| Selling, General & Admin | 17.6M | 30.03M | 35.5M | 43.75M | 41.51M |
| Operating Expenses | 95.23M | 135.93M | 150.7M | 187.66M | 171.39M |
| Depreciation & Amortization | 897K | 1.61M | 2.42M | 2.5M | 2.28M |
| EBITDA | (57.05M) | (106.51M) | (99.2M) | (127.6M) | (99.31M) |
| EBITDA Margin | -154.0% | -428.5% | -271.6% | -303.3% | -159.2% |
| Operating Income | (58.19M) | (111.07M) | (114.17M) | (145.6M) | (111.29M) |
| Operating Margin | -157.1% | -446.8% | -312.6% | -346.1% | -178.4% |
| Interest Income | 495K | 1.46M | 6.62M | 7.89M | 5.63M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 247K | 2.95M | 12.56M | 15.5M | 9.7M |
| Income Before Tax | (57.94M) | (108.12M) | (101.61M) | (130.09M) | (101.59M) |
| Pre-Tax Margin | -156.4% | -434.9% | -278.2% | -309.2% | -162.8% |
| Income Tax Expense | 292K | 54K | 134K | 208K | 4K |
| Net Income | (58.24M) | (108.18M) | (101.74M) | (130.3M) | (101.59M) |
| Net Margin | -157.2% | -435.1% | -278.5% | -309.7% | -162.9% |
| EPS (Basic) | (0.94) | (1.23) | (1.08) | (1.19) | (0.87) |
| EPS (Diluted) | (0.94) | (1.23) | (1.08) | (1.19) | (0.87) |
| Weighted Avg Shares | 62.11M | 87.82M | 94.57M | 109.23M | 116.17M |
| Weighted Avg Shares (Diluted) | 62.11M | 87.82M | 94.57M | 109.23M | 116.17M |
Tango Therapeutics, Inc.
NASDAQ:TNGX
Intrinsic Alpha fair value
Locked
Current Price
$21.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.